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Stratifying a Risk for an Increased
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ABSTRACT
Background: Recently, correlations of peak expiratory flow (PEF) variation have been shown to facilitate the
prediction of later asthma symptoms and exacerbations. However, it has not been fully examined whether or
not any patient characteristics are associated with the residual airway lability in treated asthmatics. The objec-
tive of this study is to examine a predictive marker for increased variation of PEF in patients with clinically sta-
ble asthma.
Methods: We studied 297 asthmatic patients who were monitored for PEF twice a day. Asthma Control Ques-
tionnaire (ACQ), spirometry, and exhaled nitric oxide fraction (FENO) were measured. After the assessment of
baseline values, PEF measuring was continued and associations between these clinical markers and later vari-
ation of PEF over a week (Min%Max) were investigated.
Results: 17.5% of the subjects showed increased PEF variability (Min%Max < 80%). ACQ, forced expiratory
volume in 1 s % of predicted (%FEV1), and FENO were identified as independent predictors of Min%Max < 80%.
An ACQ 0.4 yielded 96% sensitivity and 59% specificity, a %FEV1 85% yielded 62% sensitivity and 89%
specificity, and a FENO 40 ppb yielded 75% sensitivity and 90% specificity for identifying the subjects with
high variability in PEF. When we combine %FEV1 85% and FENO 40 ppb, this index showed the highest
specificity (98%) for increased PEF variability.
Conclusions: These results indicate that ACQ, %FEV1 and FENO can stratify the risk for increased variation
in airway caliber among patients with stable asthma. This may help identify subjects in whom further monitoring
of lung function fluctuations is indicated.
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ABBREVIATIONS
ACQ, Asthma Control Questionnaire; AHR, Airway hyperresponsiveness; FENO, Exhaled nitric oxide fraction;
ICS, Inhaled corticosteroids; Min%Max, The lowest PEF over a week, expressed as a percentage of the high-
est PEF; PEF, Peak expiratory flow.
INTRODUCTION
Airway hyperresponsiveness (AHR) is the suscepti-
bility of the airways to narrow excessively in re-
sponse to various stimuli and is an important physi-
ological property of asthma.1-3 The clinical conse-
quences of AHR are an exaggerated fluctuation in the
airway caliber known as airway lability.1 Indeed, it
has been reported that AHR correlates well with the
dailyweekly variation in lung function assessed by
peak expiratory flow (PEF) measurements.4-6 Among
the PEF indices, the lowest PEF over a week ex-
pressed as a percentage of the highest PEF (Min%
Max) has been shown to be the best index of airway
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Fig.　1　Study design.
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lability because it more strongly correlates with AHR
than any other pulmonary physiological parame-
ters.1,5,6
Importantly, it is widely accepted that AHR re-
mains in patients with stable asthma and it is associ-
ated with future risk of adverse outcomes.7-11 Actu-
ally, asthma management plans that include AHR
measurements showed greater efficacy in reducing
the exacerbation rate compared to plans without AHR
measurements.7,8 More recently, correlations of PEF
data have been demonstrated to facilitate the predic-
tion of later asthma symptoms and exacerbations.12-15
Thus, predicting increased fluctuation in airway cali-
ber might be useful to detect the highly reactive
asthma phenotype. However, it has not been fully ex-
amined whether or not any patient characteristics are
associated with the residual airway lability in stable
asthma.
In this prospective observational study, we simulta-
neously examined the predictive value of clinical
markers for assessing variations in airway caliber.
We studied 297 stable asthma patients who were
monitored for PEF twice a day. Asthma Control
Questionnaire (ACQ), spirometry, and exhaled nitric
oxide fraction (FENO) were measured. After the as-
sessment of the baseline values, PEF measuring was
continued and associations between these clinical
markers and later variations in PEF over a week
(Min%Max) were investigated.
METHODS
STUDY SUBJECTS
Subjects over 20 years old were eligible if they satis-
fied the standard criteria for asthma.1 We included
non-smoking asthmatic patients who were clinically
stable (no history of exacerbation of asthma) follow-
ing the treatment of inhaled corticosteroids (ICS)
with or without inhaled long-acting β2-agonist, leukot-
riene receptor antagonist, or theophylline during
andor 8 weeks prior to the study. Asthma exacerba-
tions were defined as events that required urgent ac-
tion for worsening asthma including unscheduled of-
fice visits, emergency department visits, or hospitali-
zation requiring systemic steroids therapy.16 Subjects
were excluded if they had a history of pulmonary dis-
eases except for asthma such as chronic obstructive
pulmonary disease and bronchiectasis, or were poor
adherence to asthma treatment (defined <80% adher-
ence based on prescription refill data). Specific IgE
for common inhaled allergens was examined. Positive
specific IgE to at least one allergen was assumed to
confirm the presence of atopy. This study was ap-
proved by the local ethics committee, (IRB #526) and
informed consent was obtained from each participant.
STUDY DESIGN
This was a prospective observational study (Fig. 1).
We consecutively studied non-smoking asthmatic pa-
tients who were clinically stable and monitored PEF
for more than 8 weeks (inclusion period). Patient
medical records were obtained and ACQ, spirometry,
and FENO were examined on one occasion. After the
assessment of baseline values, PEF measuring was
continued for one week, and associations between
these clinical markers and later variations of PEF
over a week (Min%Max) were investigated (observa-
tion period).
ASTHMA CONTROL VARIABLES
The pre-bronchodilator PEF was measured twice a
day using an AssessⓇ PEF meter. The Min%Max was
assumed to represent weekly PEF variability and in-
creased PEF variability was defined by Min%Max <
80%.1 The average of weekly PEF variability during
the inclusion period (8 weeks) was also obtained. The
forced vital capacity (FVC) and forced expiratory vol-
ume in 1 s (FEV1) were measured as previously de-
scribed.6 The predictive values were estimated by the
prediction formula of the Japanese Respiratory Soci-
ety. The ACQ-5 is a questionnaire that assesses
asthma condition according to five items, each of
which can be rated on a seven point scale.17 0 repre-
sents excellent asthma control and 6 represents ex-
tremely poor control. The overall score was the mean
of the five responses. The FENO level was measured
according to the standard procedures using an online
electrochemical nitric oxide analyzer (NIOX MINO;
Aerocrine AB, Solna, Sweden).18,19 Exhalations were
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Table　1　Demographic and baseline data for the study population stratifi ed by PEF variability
Variables
Low PEF variability
(Min%Max ≥ 80%)
n = 245
High PEF variability
(Min%Max < 80%)
n = 52
p value
Mean age (years) 47.7 ± 15.1 51.7 ± 13.5 0.08
Gender (male), n (%) 102 (41.6) 27 (51.9) 0.18
Body mass index (kg/mm2) 22.4 ± 3.7 23.4 ± 4.1 0.10
Ex-Smokers, n (%)  77 (31.4) 25 (48.1) <0.05
Atopy, n (%) 185 (75.5) 43 (82.7) 0.27
Asthma duration (years) 14.4 ± 8.4 13.6 ± 7.8 0.53
Dose of inhaled steroid (μg/day)† 356 ± 133 433 ± 225 <0.005
LABA use, n (%) 104 (42.4) 35 (67.3) <0.005
LTRA use, n (%)  47 (19.2) 19 (36.5) <0.005
Theophylline use, n (%) 22 (9.0)  7 (13.5) 0.32
FVC (L) 3.57 ± 0.84 3.15 ± 0.86 <0.001
FVC % of predicted (%) 105.8 ± 12.4 95.9 ± 12.3 <0.001
FEV1 (L) 2.78 ± 0.70 2.21 ± 0.72 <0.001
FEV1/FVC ratio (%) 78.1 ± 9.1 70.3 ± 10.6 <0.0001
FEV1 % of predicted (%) 100.4 ± 12.8 82.8 ± 12.3 <0.001
The average of weekly PEF variability 
during the inclusion period (%)
88.7 ± 4.8 73.2 ± 3.9 <0.0001
Min%Max (%) 89.4 ± 4.2 76.4 ± 3.0 <0.0001
FENO (ppb) 25.3 ± 12.8 51.8 ± 22.1 <0.001
Mean ACQ (points) 0.4 ± 0.4 0.9 ± 0.5 <0.001
†Dose of inhaled steroid, expressed as fl uticasone propionate equivalents. Abbreviations: Min%Max, the lowest PEF over a week, ex-
pressed as the percentage of the highest PEF; LABA, Inhaled long-acting β2-agonist; LTRA, Leukotriene receptor antagonist; FVC, forced 
vital capacity; FEV1, forced expiratory volume in one second; FENO, exhaled nitric oxide fraction; ACQ, Asthma Control Questionnaire. Mean 
(SD) values are provided unless otherwise indicated.
Table　2　Predictive value of variables in assessing the high
PEF variability according to the multivariate analysis
Variables Odds ratio (95% CI) p value
Age 1.04 (0.99-1.08) 0.13
Male 1.30 (0.43-3.92) 0.65
Body mass index 1.09 (0.96-1.24) 0.19
EX-Smokers 2.22 (0.65-7.59) 0.20
Dose of inhaled steroid† 1.00 (1.00-1.01) 0.09
LABA use 1.80 (0.58-5.60) 0.31
LTRA use 1.73 (0.55-5.47) 0.35
FVC % of predicted (%) 1.01 (0.95-1.07) 0.69
FEV1/FVC ratio (%) 1.03 (0.95-1.12) 0.45
FEV1 % of predicted (%) 1.14 (1.05-1.24) <0.005
FENO 1.08 (1.05-1.11) <0.0001
ACQ 11.86 (3.55-39.61) <0.005
†Dose of inhaled steroid, expressed as fl uticasone propionate
equivalents. Abbreviations: LABA, Inhaled long-acting β2-agonist; 
LTRA, Leukotriene receptor antagonist; FVC, forced vital capacity;
FEV1, forced expiratory volume in one second; FENO, exhaled nitric
oxide fraction; ACQ, Asthma Control Questionnaire. Multivariate
logistic regression analysis p value.
repeated to obtain two acceptable measurements
within 10% deviation, and the average of these two
values was registered.18,19
STATISTICAL ANALYSIS
All data were expressed as mean values ± SD. For
categorical variables, the numbers of observations
and percentages were given in each category. Com-
parisons between groups were performed by Fisher’s
exact test and Kruskal-Wallis test. Multivariate logis-
tic regression analysis was used to assess the associa-
tion between the binary outcome (Min%Max < 80%)
and the set of clinical covariates. The variables with p-
values < 0.20 in the univariate analysis were included
in the multivariate model. Using a receiver operating
curve, we determined the cutoff points of the predic-
tors for identifying the subjects with Min%Max < 80%.
A positive likelihood ratio [LR (+)] was calculated as
true-positive ratefalse-positive rate. An LR (+) re-
flects increased the odds of having a Min%Max < 80%
after a positive test result. A negative likelihood ratio
[LR (-)] is true-negative ratefalse-negative rate and
reflects reduced the odds of having a Min%Max < 80%
after a negative test result. A p-value of <0.05 was con-
sidered significant.
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Table　3　Sensitivity and specifi city of ACQ, %FEV1 and FENO for identifying the subjects with high PEF variability
Variables Sensitivity (%) Specifi city (%) PPV (%) NPV (%) LR (+) LR (-)
ACQ 96.2 58.8 33.1 98.6 2.33 15.3
%FEV1 61.5 89.0 54.2 91.6 5.58  2.31
FENO 75.0 89.8 60.9 94.4 7.35  3.59
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; LR (+), positive likelihood ratio (true-positive ratio/false-
positive ratio); LR (-), negative likelihood ratio (true-negative ratio/false-negative ratio); ACQ, Asthma Control Questionnaire; %FEV1, forced 
expiratory volume in one second % of predicted; FENO, exhaled nitric oxide fraction.
RESULTS
The study subjects were recruited from June 2011 to
August 2011 to avoid the influence of the cedar pollen
season in Japan. All variables were obtained from 297
patients, and 52 subjects (17.5%) showed increased
variability of PEF (Min%Max < 80%). There was no
significant difference in the PEF variability between
the inclusion period and the observation period (p =
0.32). The study subjects were divided into a low
(Min%Max80%) and high PEF variability group (Ta-
ble 1). Compared to the low PEF variability group,
the subjects with high PEF variability were more
likely to be ex-smokers (p < 0.05) and were receiving
more intensive asthma therapy (dose of ICS, inhaled
long-acting β2-agonist use, leukotriene receptor an-
tagonist use; all p < 0.005). The FVC, FVC % of pre-
dicted, FEV1, FEV1FVC ratio, and FEV1 % of pre-
dicted (%FEV1) were significantly lower in the high
PEF variability group (all p < 0.001) and this group
showed more evidence of airway inflammation de-
tected by FENO measurement and more severe
asthma symptoms (all p < 0.001).
Among the variables with p-values < 0.20 in the uni-
variate analysis, ACQ, %FEV1, and FENO were identi-
fied to be independent predictors of Min%Max < 80%
according to the multivariate analysis (OR 11.86, p <
0.005, OR 1.14, p < 0.005, and OR 1.08, p < 0.0001, re-
spectively) (Table 2). Using a receiver operating
curve for identifying the subjects with Min%Max <
80%, an ACQ0.4 yielded 96.2% sensitivity and 58.8%
specificity, a %FEV1 85% yielded 61.5% sensitivity
and 89.0% specificity, and a FENO 40 ppb yielded
75.0% sensitivity and 89.8% specificity (Table 3, Fig.
2). The area under the curve (AUC) of each variable
was 0.84, 0.84, and 0.87, respectively. To examine
these findings, we also retrospectively evaluated the
predictive values of ACQ, %FEV1, and FENO for as-
sessing increased weekly PEF variability during the
inclusion period. An ACQ0.4 yielded 88.9% sensitiv-
ity and 59.7% specificity, a %FEV1 86% yielded 57.1%
sensitivity and 88.0% specificity, and a FENO 40 ppb
yielded 65.1% sensitivity and 90.1% specificity. The
AUC of each variable was 0.80, 0.82, and 0.84, respec-
tively.
When we combine these predictors, %FEV1 85%
and FENO 40 ppb showed the highest specificity
(98.4%) for increased PEF variability (Table 4). The
distribution of the 52 subjects with high PEF variabil-
ity stratified by baseline %FEV1 and FENO is shown in
Figure 3. Twenty-six subjects with combined %FEV1
85% and FENO40 ppb had LR (+) of 26.4 and a posi-
tive predictive value of high PEF variability of 84.6%.
Alternatively, 200 subjects with combined %FEV1 >
85% and FENO < 40 ppb had LR (-) of 13.9 and nega-
tive predictive value of high PEF variability of 98.5%.
DISCUSSION
The main objective of this study was to examine the
potential of clinical markers for predicting variations
in airway caliber in patients with stable asthma. 17.5%
of the study subjects showed increased variability of
PEF and they were characterized by lower FVC and
FEV1 values, more airway inflammation, and more se-
vere asthma symptoms. Using multivariate analysis,
ACQ, %FEV1 and FENO were identified as independ-
ent predictors of increased PEF variability. When the
baseline %FEV1 85% and FENO 40 ppb were com-
bined, this index showed the highest specificity for
high PEF variability.
Current asthma guidelines have highlighted the
importance in considering the future risk of adverse
outcomes.1,20 Interestingly, several recent studies
have shown that fluctuation analysis of lung function
is useful in the assessment of the risk for future loss
of asthma control.12-15 Frey et al. found that the time
series of PEF showed long-range correlations that
changed significantly with disease severity, approach-
ing a random process with increased variability in the
most severe cases.12 Moreover, in two populations
with differing asthma severity, airway caliber fluctua-
tions were associated with asthma control and exac-
erbations.14 There is also evidence that variability of
airway caliber predicts the loss of asthma control fol-
lowing withdrawal of ICS treatment.13 These results
suggest that the characterization of fluctuations in
lung function might provide a quantitative basis for
objective risk prediction of asthma episodes. This
study firstly demonstrated that ACQ, %FEV1 and
FENO were independent predictors of later increased
variation in airway caliber. The similar predictive
properties of ACQ, %FEV1, and FENO for assessing in-
creased weekly PEF variability during the inclusion
period were consistent with these findings. In our
Prediction of Airway Lability in Asthma
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Table　4　Sensitivity and specifi city for identifying the subjects with high PEF variability, when combining each variables
Variables Sensitivity (%) Specifi city (%) PPV (%) NPV (%) LR (+) LR (-)
ACQ and %FEV1 61.5 94.3 69.6 92.0 10.8 2.45
ACQ and/or %FEV1 98.1 53.5 30.9 99.2 2.11 28.2
%FEV1 and FENO 42.3 98.4 84.6 88.9 26.4 1.71
%FEV1 and/or FENO 94.2 80.4 50.5 98.5 4.81 13.9
FENO and ACQ 75.0 92.2 67.2 94.6 9.62 3.69
FENO and/or ACQ 96.2 56.7 32.1 98.6 2.22 14.9
ACQ and %FEV1 and FENO 42.3 98.4 91.7 89.0 26.4 1.71
ACQ and/or %FEV1 and/or FENO 98.1 51.8 30.2 99.2 2.03 27.3
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; LR (+), positive likelihood ratio (true-positive ratio/false-
positive ratio); LR (-), negative likelihood ratio (true-negative ratio/false-negative ratio); ACQ, Asthma Control Questionnaire; %FEV1, forced 
expiratory volume in one second % of predicted; FENO, exhaled nitric oxide fraction.
Fig.　2　Receiver operating curve for ACQ, %FEV1 and FENO. The dot-
ted line represents ACQ, the solid thin line represents %FEV1 and the 
solid thick line represents FENO. AUC, area under the curve.
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study, approximately 18% of the subjects showed in-
creased variability of PEF, and they had more severe
asthma symptoms, more airflow limitation, and more
airway inflammation, which might reinforce this hy-
pothesis. Indeed, poor asthma control has been sug-
gested to be predictive of later asthma exacerba-
tions.20,21
Although the precise mechanism of airway lability
is uncertain, several components such as airway in-
flammation, neural reflexes, airway geometric factors
and genetic factors have been proposed to explain the
mechanism of AHR.1 Among these components, air-
way inflammation has been reported to be a key fac-
tor that seems to cause AHR via two mechanisms.3,22
It has been suggested that one component is variable
AHR, and the other is persistent AHR.22 The main
mechanism of the former AHR is active inflammation
through the release of chemical mediators from im-
mune cells, and that of the latter AHR is modification
of the airway resident cells by chronic inflamma-
tion.3,22 In our study, FENO was identified as one of
the predictors associated with high PEF variability. A
possible explanation for this is that the FENO levels
may reflect the variable AHR because sequential
FENO measuring identified the subgroup of asthma
with residual airway inflammation. Indeed, recent
studies have shown that the grouping of asthma by
FENO provides an independent classification of
asthma severity, and the subgroups with sustained
high levels of FENO are suggested to be the highly re-
Hayata A et al.
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Fig.　3　Distribution of the increased PEF variability in 52 of 297 asthmatic pa-
tients stratifi ed by baseline %FEV1 and FENO levels.
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active phenotype of asthma.23,24 We selected 40 ppb
as the cutoff point, a value that was within previously
published cutoff points for identifying subjects with
uncontrolled asthma.23-26 In this study, we also found
that %FEV1 was an independent predictor for high
PEF variability. A close association between the de-
gree of airflow limitation and AHR9,10,22 suggests that
FEV1 may reflect persistent AHR due to narrowing of
the airway caliber. A recent study demonstrated that
the majority of patients with severe asthma with low
lung function do not have irreversible airflow limita-
tion,27 which is consistent with the results of the pre-
sent study. However, FEV1 might have low sensitivity
for detecting the individuals with variable AHR.
Among the examined variables, when we com-
bined baseline %FEV1 85% and FENO 40 ppb, this
index showed the highest specificity for increased
PEF variability. Alternatively, the subjects with com-
bined %FEV1 > 85% and FENO < 40 ppb had a negative
predictive value of high PEF variability of 98.5%. This
result suggests that combined measurements of both
FEV1 and FENO may be a useful diagnostic marker
for identifying the subjects who are clinically stable
but have increased fluctuations of airway caliber. In-
terestingly, Gelb et al. have demonstrated that de-
creased FEV1 and increased FENO are independent
risk factors for exacerbations of asthma.28
ACQ is a well validated composite measure for
asthma control17 and it was also related to increased
variation of airway caliber. ACQ-defined asthma con-
trol is identified according to the following criteria:
well controlled 0.75 and inadequately controlled 
1.5.29 In our study, ACQ 0.4 yielded 96.2% of sensi-
tivity and 58.8% of specificity for identifying the sub-
jects with high PEF variability. ACQ was suggested
to be a good screening test for exaggerated variation
in lung function, but it is necessary to note that the
specificity reduced when stricter cutoff point was ap-
plied.
There would be some limitations in our study.
First, a selection bias is possible because it was a
purely observational study. Second, although all sub-
jects had been carefully educated on the correct PEF
measurements, we could not verify their techniques
objectively. Finally, the study period was too short to
assess the relationship between the airway caliber
fluctuations and loss of asthma control.
In conclusion, this study indicates that ACQ,
%FEV1 and FENO can stratify the risk for increased
variation in airway caliber among patients with stable
asthma. This may help identify subjects in whom fur-
ther monitoring of lung function fluctuations is indi-
cated.
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